Imunon IncNASDAQ:IMNN
- LAST PRICE1.1700
- TODAY'S CHANGE (%)0.0450 (4.0000%)
- Bid / Lots1.1400/ 19
- Ask / Lots1.4700/ 1
- Open / Previous Close1.0900 / 1.1250
- Day Range
- 52 Week Range
- Volume95,137
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMNN |
|---|---|---|
| 09:32 ET | 2577 | 1.14 |
| 09:36 ET | 100 | 1.12 |
| 09:38 ET | 2088 | 1.12 |
| 09:45 ET | 100 | 1.16 |
| 09:52 ET | 4134 | 1.11 |
| 09:54 ET | 100 | 1.16 |
| 09:59 ET | 1800 | 1.1594 |
| 10:03 ET | 1943 | 1.11 |
| 10:10 ET | 2571 | 1.1008 |
| 10:12 ET | 5686 | 1.11 |
| 10:15 ET | 1400 | 1.1151 |
| 10:17 ET | 100 | 1.1399 |
| 10:32 ET | 206 | 1.14 |
| 10:37 ET | 100 | 1.14 |
| 11:11 ET | 10037 | 1.115 |
| 11:15 ET | 994 | 1.1 |
| 11:18 ET | 1640 | 1.14 |
| 11:22 ET | 100 | 1.12 |
| 11:33 ET | 401 | 1.1383 |
| 11:42 ET | 483 | 1.12 |
| 11:51 ET | 100 | 1.12 |
| 12:07 ET | 100 | 1.11 |
| 12:23 ET | 1000 | 1.125 |
| 12:25 ET | 100 | 1.11 |
| 12:36 ET | 100 | 1.11 |
| 12:45 ET | 100 | 1.12 |
| 12:52 ET | 1500 | 1.13 |
| 12:56 ET | 100 | 1.16 |
| 12:59 ET | 244 | 1.14 |
| 01:01 ET | 400 | 1.14 |
| 01:03 ET | 1830 | 1.13 |
| 01:12 ET | 100 | 1.12 |
| 01:14 ET | 300 | 1.12 |
| 01:19 ET | 1900 | 1.13 |
| 01:24 ET | 500 | 1.12 |
| 01:26 ET | 350 | 1.1201 |
| 01:28 ET | 100 | 1.12 |
| 01:33 ET | 100 | 1.12 |
| 01:42 ET | 330 | 1.1266 |
| 01:48 ET | 100 | 1.12 |
| 02:00 ET | 100 | 1.125 |
| 02:08 ET | 100 | 1.12 |
| 02:13 ET | 1100 | 1.13 |
| 02:15 ET | 1204 | 1.13 |
| 02:22 ET | 200 | 1.13 |
| 02:26 ET | 11783 | 1.1598 |
| 02:36 ET | 100 | 1.1337 |
| 02:40 ET | 1000 | 1.13 |
| 02:45 ET | 7919 | 1.15 |
| 02:47 ET | 700 | 1.15 |
| 02:51 ET | 6500 | 1.145 |
| 02:58 ET | 3100 | 1.14 |
| 03:05 ET | 200 | 1.14 |
| 03:07 ET | 1100 | 1.145 |
| 03:18 ET | 3000 | 1.16 |
| 03:21 ET | 117 | 1.15 |
| 03:25 ET | 100 | 1.14 |
| 03:32 ET | 100 | 1.14 |
| 03:38 ET | 315 | 1.1401 |
| 03:45 ET | 100 | 1.14 |
| 03:48 ET | 100 | 1.14 |
| 03:50 ET | 100 | 1.14 |
| 03:52 ET | 100 | 1.14 |
| 03:54 ET | 400 | 1.16 |
| 03:56 ET | 1200 | 1.16 |
| 03:57 ET | 1100 | 1.16 |
| 03:59 ET | 300 | 1.17 |
Apr 18, 2024
DJ Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine, from 10:23AM ET on Thursday Apr 18, 2024 by Dow Jones
10:23AM ET on Thursday Apr 18, 2024 by Dow JonesIMUNON's IND Application Cleared to Begin Human Testing of IMNN-101, from 8:30AM ET on Thursday Apr 18, 2024 by Dow Jones
8:30AM ET on Thursday Apr 18, 2024 by Dow JonesIMUNON's IND Application Cleared to Begin Human Testing of IMNN-101, from 8:30AM ET on Thursday Apr 18, 2024 by Dow Jones
8:30AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 11, 2024
IMUNON Reports Compliance with Nasdaq Listing Requirements, from 8:00AM ET on Thursday Apr 11, 2024 by Dow Jones
8:00AM ET on Thursday Apr 11, 2024 by Dow JonesIMUNON Reports Compliance with Nasdaq Listing Requirements, from 8:00AM ET on Thursday Apr 11, 2024 by Dow Jones
8:00AM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Imunon Inc | 11.0M | -0.5x | --- |
Hepion Pharmaceuticals Inc | 11.0M | -0.2x | --- |
Monopar Therapeutics Inc | 11.2M | -1.0x | --- |
National Graphite Corp | 10.5M | -3.1x | --- |
Aslan Pharmaceuticals Ltd | 11.6M | -0.2x | --- |
Connect Biopharma Holdings Ltd | 84.8M | 0.0x | --- |
Company Information
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Contact Information
- Headquarters
- 997 Lenox Dr Ste 100LAWRENCEVILLE, NJ, United States 08648
- Phone
- 609-896-9100
- Fax
- 609-896-2200
Executives
- Executive Chairman of the Board
- Michael Tardugno
- Chief Financial Officer, Executive Vice President
- Jeffrey Church
- Executive Vice President, Chief Scientific Officer
- Khursheed Anwer
- Executive Vice President, Chief Medical Officer
- Sebastien Hazard
- Independent Director
- Donald Braun
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 9.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.07 |
EPS | $-2.17 |
Book Value | $1.42 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
